尿间皮素对早期卵巢癌的诊断敏感性高于血清间皮素、尿游离人绒毛膜促性腺激素β亚基和尿人绒毛膜促性腺激素β核心片段。

Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.

作者信息

Badgwell Donna, Lu Zhen, Cole Laurence, Fritsche Herbert, Atkinson Edward N, Somers Elizabeth, Allard Jeffrey, Moore Richard G, Lu Karen H, Bast Robert C

机构信息

Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Box 355, 1515 Holcombe Boulevard, Houston, TX 77030, and Program in Women's Oncology, Women's and Infants' Hospital, Providence, RI 02905, USA.

出版信息

Gynecol Oncol. 2007 Sep;106(3):490-7. doi: 10.1016/j.ygyno.2007.04.022. Epub 2007 May 25.

DOI:10.1016/j.ygyno.2007.04.022

PMID:17532030

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3374586/

Abstract

OBJECTIVES

Early detection of ovarian cancer should improve overall survival. Multiple serum markers have been evaluated as possible tests to detect early stage disease, but few urine markers have been studied. Mesothelin has been detected in serum from patients with ovarian cancer, but has not been previously reported in urine.

METHODS

Mesothelin was assayed in the serum and in the urine from 28 patients with early stage (I/II) invasive epithelial ovarian cancers, 111 with advanced stage (III/IV) invasive disease and 19 with tumors of low malignant potential. Marker values have been compared to those in healthy controls and 115 patients with benign pelvic masses. Thresholds were set to include 95% of mesothelin values for 127 sera and 89 urines from healthy women. Urine values were considered: (1) as assayed; (2) normalized using the ratio of serum to urine creatinine; and (3) normalized using the Cockroft-Gault formula for glomerular filtration rate (GFR). Urines were also assayed for human chorionic gonadotropin (hCG) free beta subunit and beta subunit core fragment and similarly normalized.

RESULTS

Optimal sensitivity for early stage disease was obtained when urine mesothelin was normalized using GFR. A greater fraction of patients with early stage disease was detected with the mesothelin urine assay (42%) than with the serum assay (12%). Similarly, 75% of patients with advanced ovarian cancer had elevated mesothelin in urine compared to 48% in serum. Serum and urine levels of mesothelin correlated for early (p=0.02) and late (p<0.001) disease. Urine mesothelin exhibited greater sensitivity for early stage ovarian cancer than did hCG free beta subunit or beta subunit core fragment and complementarity was not observed.

CONCLUSION

Urine mesothelin deserves further evaluation as a biomarker for detection of early stage ovarian cancer in combination with other urinary markers.

摘要

目的

早期发现卵巢癌应能提高总体生存率。多种血清标志物已被评估作为检测早期疾病的可能检测方法，但很少有尿液标志物被研究。间皮素已在卵巢癌患者的血清中被检测到，但此前尚未在尿液中报道。

方法

对28例早期（I/II期）浸润性上皮性卵巢癌患者、111例晚期（III/IV期）浸润性疾病患者和19例低恶性潜能肿瘤患者的血清和尿液进行间皮素检测。将标志物值与健康对照者以及115例良性盆腔肿块患者的标志物值进行比较。设定阈值以纳入127份健康女性血清和89份尿液中间皮素值的95%。尿液值被考虑为：（1）按检测值；（2）使用血清与尿肌酐比值进行标准化；（3）使用Cockcroft-Gault公式计算肾小球滤过率（GFR）进行标准化。还对尿液进行人绒毛膜促性腺激素（hCG）游离β亚基和β亚基核心片段检测，并进行类似的标准化。

结果

当使用GFR对尿液间皮素进行标准化时，可获得早期疾病的最佳敏感性。与血清检测（12%）相比，间皮素尿液检测发现更大比例的早期疾病患者（42%）。同样，75%的晚期卵巢癌患者尿液中间皮素升高，而血清中这一比例为48%。早期（p=0.0

相似文献

Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.

Gynecol Oncol. 2007 Sep;106(3):490-7. doi: 10.1016/j.ygyno.2007.04.022. Epub 2007 May 25.

HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.

Asian Pac J Cancer Prev. 2010;11(1):111-6.

Urinary human chorionic gonadotropin free beta-subunit and beta-core fragment: a new marker of gynecological cancers.

Cancer Res. 1988 Mar 1;48(5):1356-60.

Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.

Anticancer Res. 1999 Nov-Dec;19(6C):5551-7.

Assessment of urinary beta-core fragment of human chorionic gonadotropin as a new tumor marker of lung cancer.

Cancer. 1994 Jun 1;73(11):2745-52. doi: 10.1002/1097-0142(19940601)73:11<2745::aid-cncr2820731116>3.0.co;2-v.

Urinary chorionic gonadotropin subunits and beta-core in nonpregnant women. A study of benign and malignant gynecologic disorders.

Cancer. 1993 Jun 15;71(12):4124-30. doi: 10.1002/1097-0142(19930615)71:12<4124::aid-cncr2820711252>3.0.co;2-p.

Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor.

Anticancer Res. 2006 Nov-Dec;26(6C):4721-8.

Combination assay of urinary beta-core fragment of human chorionic gonadotropin with serum tumor markers in gynecologic cancers.

Jpn J Cancer Res. 1995 Aug;86(8):783-9. doi: 10.1111/j.1349-7006.1995.tb02469.x.

Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.

Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1365-72. doi: 10.1158/1055-9965.EPI-08-1034.

Evaluation of serum mesothelin in malignant and benign ovarian masses.

Arch Gynecol Obstet. 2014 Jul;290(1):107-13. doi: 10.1007/s00404-014-3147-2. Epub 2014 Jan 21.

引用本文的文献

Detecting vascular normalization in epithelial ovarian cancer.

Med Oncol. 2025 Aug 3;42(9):401. doi: 10.1007/s12032-025-02929-5.

Modern Emerging Biosensing Methodologies for the Early Diagnosis and Screening of Ovarian Cancer.

Biosensors (Basel). 2025 Mar 21;15(4):203. doi: 10.3390/bios15040203.

Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4.

Ther Adv Med Oncol. 2024 Feb 29;16:17588359241233225. doi: 10.1177/17588359241233225. eCollection 2024.

High-Grade Serous Ovarian Cancer-A Risk Factor Puzzle and Screening Fugitive.

Biomedicines. 2024 Jan 19;12(1):229. doi: 10.3390/biomedicines12010229.

Evaluation of the Potential Diagnostic Utility of the Determination of Selected Immunological and Molecular Parameters in Patients with Ovarian Cancer.

Diagnostics (Basel). 2023 May 12;13(10):1714. doi: 10.3390/diagnostics13101714.

Exosomes: A potential tool for immunotherapy of ovarian cancer.

Front Immunol. 2023 Jan 18;13:1089410. doi: 10.3389/fimmu.2022.1089410. eCollection 2022.

The Role of Mesothelin Expression in Serous Ovarian Carcinoma: Impacts on Diagnosis, Prognosis, and Therapeutic Targets.

Cancers (Basel). 2022 May 3;14(9):2283. doi: 10.3390/cancers14092283.

Urinary biomarkers for the detection of ovarian cancer: a systematic review.

Carcinogenesis. 2022 May 19;43(4):311-320. doi: 10.1093/carcin/bgac016.

Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer.

Int J Mol Sci. 2021 Dec 20;22(24):13650. doi: 10.3390/ijms222413650.

Evaluation of the potential of Pap test fluid and cervical swabs to serve as clinical diagnostic biospecimens for the detection of ovarian cancer by mass spectrometry-based proteomics.

Clin Proteomics. 2021 Jan 7;18(1):4. doi: 10.1186/s12014-020-09309-3.

本文引用的文献

Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.

Clin Cancer Res. 2006 Jan 15;12(2):432-41. doi: 10.1158/1078-0432.CCR-05-0461.

Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.

J Clin Oncol. 2005 Nov 1;23(31):7919-26. doi: 10.1200/JCO.2005.01.6642.

Potential markers that complement expression of CA125 in epithelial ovarian cancer.

Gynecol Oncol. 2005 Nov;99(2):267-77. doi: 10.1016/j.ygyno.2005.06.040. Epub 2005 Aug 2.

Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.

Gynecol Oncol. 2005 Mar;96(3):684-94. doi: 10.1016/j.ygyno.2004.11.039.

Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.

Gynecol Oncol. 2004 Oct;95(1):9-15. doi: 10.1016/j.ygyno.2004.07.039.

Characterization of human mesothelin transcripts in ovarian and pancreatic cancer.

BMC Cancer. 2004 May 12;4:19. doi: 10.1186/1471-2407-4-19.

Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.

J Biol Chem. 2004 Mar 5;279(10):9190-8. doi: 10.1074/jbc.M312372200. Epub 2003 Dec 15.

Status of tumor markers in ovarian cancer screening.

J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s. doi: 10.1200/JCO.2003.01.068.

Temperature range of thermodynamic stability for the native state of reversible two-state proteins.

Biochemistry. 2003 May 6;42(17):4864-73. doi: 10.1021/bi027184+.

Genetic analysis of early- versus late-stage ovarian tumors.

Cancer Res. 2001 Aug 1;61(15):5895-904.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

尿间皮素对早期卵巢癌的诊断敏感性高于血清间皮素、尿游离人绒毛膜促性腺激素β亚基和尿人绒毛膜促性腺激素β核心片段。

Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.

作者信息

Badgwell Donna, Lu Zhen, Cole Laurence, Fritsche Herbert, Atkinson Edward N, Somers Elizabeth, Allard Jeffrey, Moore Richard G, Lu Karen H, Bast Robert C

机构信息

出版信息

Gynecol Oncol. 2007 Sep;106(3):490-7. doi: 10.1016/j.ygyno.2007.04.022. Epub 2007 May 25.

DOI:10.1016/j.ygyno.2007.04.022

PMID:17532030

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3374586/

Abstract

OBJECTIVES

METHODS

RESULTS

CONCLUSION

Urine mesothelin deserves further evaluation as a biomarker for detection of early stage ovarian cancer in combination with other urinary markers.

摘要

尿间皮素对早期卵巢癌的诊断敏感性高于血清间皮素、尿游离人绒毛膜促性腺激素β亚基和尿人绒毛膜促性腺激素β核心片段。

Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.

作者信息

机构信息

出版信息

OBJECTIVES

METHODS

RESULTS

CONCLUSION

目的

方法

结果

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

尿间皮素对早期卵巢癌的诊断敏感性高于血清间皮素、尿游离人绒毛膜促性腺激素β亚基和尿人绒毛膜促性腺激素β核心片段。

Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.

作者信息

机构信息

出版信息

OBJECTIVES

METHODS

RESULTS

CONCLUSION

目的

方法

结果